TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 31640628

Group type: EXPERIMENTAL
Intervention: Evaluation by 5 independent pancreatic surgeons using pretherapeutic CT or MRI scans.
Number of subjects: 200
Study: 28657702

Group type: EXPERIMENTAL
Intervention: Sodium monofluorophosphate (SMFP) dentifrice containing 1500 ppm F with 5% calcium sodium phosphosilicate (CSPS)
Number of subjects: 77

Group type: COMPARATOR
Intervention: Sodium monofluorophosphate (SMFP) dentifrice containing 1500 ppm F with 0% CSPS
Number of subjects: 77
Study: 26210757

Group type: EXPERIMENTAL
Intervention: Sequence-positive participants
Number of subjects: 182
Study: 24450890

Group type: EXPERIMENTAL
Intervention: Solanezumab (400 mg administered intravenously every 4 weeks for 18 months)
Number of subjects: 2052

Group type: COMPARATOR
Intervention: Solanezumab
Number of subjects: 2052
Study: 21104046

Group type: EXPERIMENTAL
Intervention: Minute ventilation (MV) sensor
Number of subjects: 1000

Group type: COMPARATOR
Intervention: Accelerometer (XL) sensor
Number of subjects: 1000
Study: 20426290

Group type: EXPERIMENTAL
Intervention: Polygalactin‐910 continuous suturing (Group A)
Number of subjects: 174

Group type: EXPERIMENTAL
Intervention: Polygalactin‐910 interrupted suturing (Group B)
Number of subjects: 174

Group type: COMPARATOR
Intervention: Polypropylene continuous suturing (Group C)
Number of subjects: 174

Group type: COMPARATOR
Intervention: Polypropylene interrupted suturing (Group D)
Number of subjects: 174
Study: 17167126

Group type: EXPERIMENTAL
Intervention: Flexible coping psychotherapy (FCP)
Number of subjects: 75

Group type: COMPARATOR
Intervention: Supportive psychotherapy (SPP)
Number of subjects: 75
Study: 15170011

Group type: EXPERIMENTAL
Intervention: Treatment with single dose (2 g) metronidazole and clotrimazole cream for 3 days, randomized to follow-up strategies
Number of subjects: 726

Group type: COMPARATOR
Intervention: Follow-up strategy A: Come back on day 7 only if no improvement in discharge
Number of subjects: 726

Group type: COMPARATOR
Intervention: Follow-up strategy B: Come back on day 7 regardless of response to treatment
Number of subjects: 726

Group type: COMPARATOR
Intervention: Comprehensive interventions for sex workers in Ghana and Bénin
Number of subjects: 726
Study: 12041052

Group type: EXPERIMENTAL
Intervention: Open-suction method
Number of subjects: 20

Group type: COMPARATOR
Intervention: Closed-suction method
Number of subjects: 20
Study: 9660431

Group type: COMPARATOR
Intervention: Leuprolide acetate (3.75 mg every 28 days IM) + placebo tablets (group A)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Leuprolide acetate (3.75 mg every 28 days IM) + 2.5 mg of tibolone per os (group B)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Leuprolide acetate + placebo (group A)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Leuprolide acetate + tibolone (group B)
Number of subjects: 50
Study: 7640448

Group type: EXPERIMENTAL
Intervention: Prophylactic portal infusion chemotherapy (PPIC)
Number of subjects: 110

Group type: COMPARATOR
Intervention: Control group (no PPIC)
Number of subjects: 110
Study: 2653300

Group type: EXPERIMENTAL
Intervention: misonidazole
Number of subjects: 89

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 89
Study: 782700

Group type: EXPERIMENTAL
Intervention: Combination of BCNU, vinblastine, cyclophosphamide, procarbazine, and prednisone
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Combination of mechlorethamine, vincristine, prednisone, and procarbazine (MOPP)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: BCNU given orally
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Methyl‐CCNU given orally
Number of subjects: 0
Study: 31715173

Group type: EXPERIMENTAL
Intervention: Individualized quarterly learning curves
Number of subjects: 132

Group type: COMPARATOR
Intervention: Standard feedback
Number of subjects: 132
Study: 31337570

Group type: COMPARATOR
Intervention: Iliac crest bone graft with HAM coverage (n=5)
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Iliac bone grafts covered with HAM loaded with BFSCs (n=4)
Number of subjects: 9
Study: 28058589

Group type: EXPERIMENTAL
Intervention: Atomoxetine
Number of subjects: 524

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 524
Study: 26198864

Group type: EXPERIMENTAL
Intervention: General palpation method
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Four-finger technique
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Neck crease method
Number of subjects: 50
Study: 24033239

Group type: EXPERIMENTAL
Intervention: Group Stepping Stones Triple P (GSSTP)
Number of subjects: 52
Study: 21862829

Group type: EXPERIMENTAL
Intervention: Opioid blockade (8 mg of naloxone)
Number of subjects: 179

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 179
Study: 19696704

Group type: EXPERIMENTAL
Intervention: 200 microg oral transmucosal fentanyl citrate
Number of subjects: 35

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 35
Study: 17659254

Group type: EXPERIMENTAL
Intervention: Orlistat + CBTgsh
Number of subjects: 50

Group type: COMPARATOR
Intervention: Placebo + CBTgsh
Number of subjects: 50
Study: 15254883

Group type: EXPERIMENTAL
Intervention: Early nighttime hypoglycemia
Number of subjects: 0

Group type: COMPARATOR
Intervention: Morning hypoglycemia
Number of subjects: 0
Study: 11488781

Group type: EXPERIMENTAL
Intervention: Nifedipine
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study: 9766793

Group type: EXPERIMENTAL
Intervention: Recombinant human erythropoietin (40 IU kg(‐1)i.v., three times weekly)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Control subjects (24 subjects)
Number of subjects: 12
Study: 8001440

Group type: EXPERIMENTAL
Intervention: Subconjunctival triamcinolone acetonide (TA)
Number of subjects: 89

Group type: COMPARATOR
Intervention: Control group (no TA)
Number of subjects: 89
Study: 2490828

Group type: EXPERIMENTAL
Intervention: Antihypertensive drug treatment
Number of subjects: 420000

Group type: COMPARATOR
Intervention: Prolonged difference of about 6 mm Hg in DBP
Number of subjects: 420000
Study: 6179

Group type: COMPARATOR
Intervention: Propranolol (80 mg)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Practolol (250 mg)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Metoprolol (100 mg)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Tolamolol (100 mg)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Tolamolol (200 mg)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study: 31466229

Group type: EXPERIMENTAL
Intervention: Combined Intervention (CI) - cognitive stimulation program (CSP) and physical exercise program (PEP), 3 times a week for 12 weeks
Number of subjects: 44

Group type: COMPARATOR
Intervention: Standard care (Control Group)
Number of subjects: 44
Study: 28945186

Group type: EXPERIMENTAL
Intervention: Shared decision-making system
Number of subjects: 56

Group type: COMPARATOR
Intervention: Treatment as usual
Number of subjects: 56
Study: 26102617

Group type: EXPERIMENTAL
Intervention: Double ureteral stent placement
Number of subjects: 55

Group type: COMPARATOR
Intervention: Single ureteral stent placement
Number of subjects: 55
Study: 23084124

Group type: EXPERIMENTAL
Intervention: Anwar technique
Number of subjects: 57

Group type: COMPARATOR
Intervention: Melles technique
Number of subjects: 57
Study: 16878679

Group type: EXPERIMENTAL
Intervention: Denzir (DZ) system
Number of subjects: 18

Group type: COMPARATOR
Intervention: In-Ceram Zirconia (InZ) system
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Both systems
Number of subjects: 18
Study: 12932213

Group type: EXPERIMENTAL
Intervention: Assigned subordinates who initially wanted to be dominant
Number of subjects: 138

Group type: COMPARATOR
Intervention: Assigned high-dominance individuals
Number of subjects: 138
Study: 10479194

Group type: EXPERIMENTAL
Intervention: 6.6 g n‐3 PUFA
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: 2.0 g n‐3 PUFA
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo (olive oil)
Number of subjects: 60
Study: 8626360

Group type: EXPERIMENTAL
Intervention: Citalopram
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Nefazodone
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Imipramine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 1649840

Group type: EXPERIMENTAL
Intervention: Oral administration of estrogen alone
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: Percutaneous administration of estrogen
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: Utrogestan in combination with oral estrogen
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: Utrogestan with percutaneous estrogen
Number of subjects: 63
Study: 6359083

Group type: EXPERIMENTAL
Intervention: Propiram fumarate 50 mg
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Codeine sulfate 60 mg
Number of subjects: 120

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 120
Study: 30262155

Group type: EXPERIMENTAL
Intervention: Treatment with T4 normalization after 5 months (median and percentiles 2.0-10.5 months)
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Patients with PAH
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Patients without cardiovascular disease after T4 normalization
Number of subjects: 32
Study: 27357445

Group type: EXPERIMENTAL
Intervention: FCR (fludarabine and cyclophosphamide with rituximab)
Number of subjects: 817

Group type: COMPARATOR
Intervention: FC (fludarabine and cyclophosphamide)
Number of subjects: 817
Study: 26155932

Group type: EXPERIMENTAL
Intervention: HITSystem intervention at intervention hospitals (n=3)
Number of subjects: 720

Group type: COMPARATOR
Intervention: Standard care at matched control sites (n=3)
Number of subjects: 720
Study: 23450336

Group type: EXPERIMENTAL
Intervention: H‐IVIG
Number of subjects: 35

Group type: COMPARATOR
Intervention: IV immunoglobulin (control)
Number of subjects: 35
Study: 21320840

Group type: EXPERIMENTAL
Intervention: Specialized interprofessional team approach to community-based stroke rehabilitation (n=52)
Number of subjects: 101

Group type: COMPARATOR
Intervention: Usual home care (n=49)
Number of subjects: 101
Study: 18996068

Group type: EXPERIMENTAL
Intervention: Psychoeducational message (beauty ideals)
Number of subjects: 159

Group type: EXPERIMENTAL
Intervention: Psychoeducational message (marketing strategies)
Number of subjects: 159

Group type: EXPERIMENTAL
Intervention: Photo exposure (attractive females)
Number of subjects: 159

Group type: COMPARATOR
Intervention: Photo exposure (household products)
Number of subjects: 159
Study: 16683273

Group type: EXPERIMENTAL
Intervention: Sirolimus-eluting stents (SES)
Number of subjects: 70

Group type: COMPARATOR
Intervention: Paclitaxel-eluting stents (PES)
Number of subjects: 70
Study: 14595048

Group type: EXPERIMENTAL
Intervention: Diphtheria-tetanus-acellular pertussis vaccine (DTaP)
Number of subjects: 788

Group type: COMPARATOR
Intervention: Diphtheria-tetanus vaccine only (DT)
Number of subjects: 788

Group type: EXPERIMENTAL
Intervention: Culture-positive patients
Number of subjects: 788

Group type: EXPERIMENTAL
Intervention: Antibiotic treatment
Number of subjects: 788

Group type: EXPERIMENTAL
Intervention: Girls (after 3 years of age)
Number of subjects: 788

Group type: EXPERIMENTAL
Intervention: Age
Number of subjects: 788
Study: 10800239

Group type: EXPERIMENTAL
Intervention: Midazolam
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Flumazenil
Number of subjects: 14

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Flumazenil without midazolam
Number of subjects: 14
Study: 8804804

Group type: EXPERIMENTAL
Intervention: 400 micrograms oral misoprostol
Number of subjects: 70

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 70
Study: 1615883

Group type: EXPERIMENTAL
Intervention: dF 15 mg twice daily for 26 weeks
Number of subjects: 45

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 45
Study: 6151206

Group type: EXPERIMENTAL
Intervention: Divided dosage (DD) of prazepam 40 mg per day (10 mg in the morning, 10 mg at noon, 20 mg in the evening)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Single dosage (SD) of prazepam 40 mg per day (40 mg in the evening)
Number of subjects: 20
Study: 30654138

Group type: EXPERIMENTAL
Intervention: Cubist (M5 rule‐based model with corrections based on nearest neighbors)
Number of subjects: 83

Group type: EXPERIMENTAL
Intervention: M5 regression tree
Number of subjects: 83

Group type: EXPERIMENTAL
Intervention: extremely randomized regression trees (extraTrees)
Number of subjects: 83

Group type: EXPERIMENTAL
Intervention: least angle regression (lars)
Number of subjects: 83

Group type: EXPERIMENTAL
Intervention: non‐negative least squares (nnls)
Number of subjects: 83

Group type: EXPERIMENTAL
Intervention: Committee of neural networks (avNNet)
Number of subjects: 83

Group type: EXPERIMENTAL
Intervention: random forest (rf)
Number of subjects: 83

Group type: EXPERIMENTAL
Intervention: ε‐support vector regression (svr)
Number of subjects: 83
Study: 29738057

Group type: EXPERIMENTAL
Intervention: TAP block with 30 mL 0.25% levobupivacaine
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Local anesthetic infiltration with 20 mL of levobupivacaine 0.5%
Number of subjects: 75

Group type: COMPARATOR
Intervention: Control group (no TAP block or LAI)
Number of subjects: 75
Study: 27495137

Group type: EXPERIMENTAL
Intervention: C-reactive protein point-of-care testing
Number of subjects: 2037

Group type: COMPARATOR
Intervention: Routine care
Number of subjects: 2037
Study: 25196314

Group type: EXPERIMENTAL
Intervention: Adjunctive aripiprazole
Number of subjects: 0
Study: 23015563

Group type: EXPERIMENTAL
Intervention: Double-bundle technique
Number of subjects: 60

Group type: COMPARATOR
Intervention: Single-bundle technique
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: AM bundle in double-bundle group
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: PL bundle in double-bundle technique
Number of subjects: 60
Study: 21034545

Group type: EXPERIMENTAL
Intervention: Vital capacity induction with 8% sevoflurane at 6 L/min
Number of subjects: 51

Group type: COMPARATOR
Intervention: Tidal breathing induction with 8% sevoflurane at 6 L/min
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: Vital capacity induction
Number of subjects: 51

Group type: COMPARATOR
Intervention: Tidal breathing induction
Number of subjects: 51
Study: 17413870

Group type: EXPERIMENTAL
Intervention: Sunflower seed oil (SSO)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Aquaphor
Number of subjects: 0

Group type: COMPARATOR
Intervention: Untreated control group
Number of subjects: 0
Study: 16351335

Group type: EXPERIMENTAL
Intervention: Early Head Start program
Number of subjects: 3001

Group type: EXPERIMENTAL
Intervention: Early Head Start program with a mix of home-visiting and center-based services
Number of subjects: 3001

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 3001
Study: 11898016

Group type: EXPERIMENTAL
Intervention: Quantitative feedback
Number of subjects: 71

Group type: EXPERIMENTAL
Intervention: Qualitative feedback
Number of subjects: 71

Group type: EXPERIMENTAL
Intervention: Light force conditions
Number of subjects: 71

Group type: EXPERIMENTAL
Intervention: Heavy force conditions
Number of subjects: 71

Group type: EXPERIMENTAL
Intervention: Trial blocks
Number of subjects: 71

Group type: EXPERIMENTAL
Intervention: Retention phase
Number of subjects: 71

Group type: EXPERIMENTAL
Intervention: Time between acquisition and retention trials
Number of subjects: 71

Group type: EXPERIMENTAL
Intervention: Trial blocks during retention phase
Number of subjects: 71

Group type: EXPERIMENTAL
Intervention: Group trial block interaction for /CE/
Number of subjects: 71

Group type: EXPERIMENTAL
Intervention: Overall conclusion
Number of subjects: 71
Study: 10437419

Group type: EXPERIMENTAL
Intervention: Thiopental 5 mg/kg
Number of subjects: 165

Group type: EXPERIMENTAL
Intervention: Etomidate 0.3 mg/kg
Number of subjects: 165

Group type: EXPERIMENTAL
Intervention: Propofol 2.5 mg/kg
Number of subjects: 165
Study: 7568344

Group type: EXPERIMENTAL
Intervention: Indometacin
Number of subjects: 7

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 7
Study: 1968919

Group type: EXPERIMENTAL
Intervention: Cetirizine 20 mg (three daily doses)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Cetirizine (5, 10, and 20 mg)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Cetirizine and Albuterol
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Albuterol 4 mg
Number of subjects: 16
Study: 395955

Group type: EXPERIMENTAL
Intervention: Nicergoline (3 x 1 dragée at 10 mg for 12 weeks)
Number of subjects: 56

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 56
Study: 30932154

Group type: EXPERIMENTAL
Intervention: Graphic health warning labels present on cigarette packages
Number of subjects: 294

Group type: COMPARATOR
Intervention: Cigarette packages without graphic health warning labels
Number of subjects: 294
Study: 28631849

Group type: EXPERIMENTAL
Intervention: automated closed-loop therapy
Number of subjects: 16

Group type: COMPARATOR
Intervention: sensor-augmented pump therapy
Number of subjects: 16
Study: 26392766

Group type: EXPERIMENTAL
Intervention: Indacaterol (150 μg)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study: 23404882

Group type: EXPERIMENTAL
Intervention: Caring/Task-Involving (C/TI) climate
Number of subjects: 107

Group type: COMPARATOR
Intervention: Ego-Involving (EI) climate
Number of subjects: 107
Study: 20965155

Group type: EXPERIMENTAL
Intervention: Endogenous estrogen exposure
Number of subjects: 53

Group type: EXPERIMENTAL
Intervention: Length of reproductive years of life
Number of subjects: 53

Group type: COMPARATOR
Intervention: Length of hormone therapy (HT) use
Number of subjects: 53
Study: 19845991

Group type: EXPERIMENTAL
Intervention: Self-report data collection
Number of subjects: 175

Group type: EXPERIMENTAL
Intervention: Care provider registrations
Number of subjects: 175

Group type: COMPARATOR
Intervention: Hospitalizations
Number of subjects: 175

Group type: COMPARATOR
Intervention: Physiotherapist visits
Number of subjects: 175

Group type: COMPARATOR
Intervention: All other types of care
Number of subjects: 175
Study: 16150840

Group type: EXPERIMENTAL
Intervention: Hypergravity exposure in supine posture
Number of subjects: 4

Group type: EXPERIMENTAL
Intervention: Hypergravity exposure in prone posture
Number of subjects: 4
Study: 15701187

Group type: EXPERIMENTAL
Intervention: Laparoscopic-assisted hysterectomy
Number of subjects: 46

Group type: COMPARATOR
Intervention: Abdominal hysterectomy
Number of subjects: 46
Study: 11699735

Group type: EXPERIMENTAL
Intervention: Crest SpinBrush (experimental toothbrush)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Colgate Navigator (control toothbrush)
Number of subjects: 40
Study: 9183201

Group type: EXPERIMENTAL
Intervention: Antibiotics
Number of subjects: 6

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6
Study: 8314427

Group type: EXPERIMENTAL
Intervention: Intensified health education
Number of subjects: 817

Group type: COMPARATOR
Intervention: Usual care (Control)
Number of subjects: 817

Group type: EXPERIMENTAL
Intervention: Comparison to general population
Number of subjects: 817
Study: 2882420

Group type: EXPERIMENTAL
Intervention: Coronary‐artery bypass surgery plus medical therapy
Number of subjects: 468

Group type: COMPARATOR
Intervention: Medical therapy alone
Number of subjects: 468
Study: 29164661

Group type: EXPERIMENTAL
Intervention: Alcohol-containing mouthrinse
Number of subjects: 163

Group type: COMPARATOR
Intervention: Alcohol-free mouthrinse
Number of subjects: 163
Study: 26545320

Group type: EXPERIMENTAL
Intervention: Antiplatelet or anticoagulant drugs
Number of subjects: 1185

Group type: COMPARATOR
Intervention: No antiplatelet or anticoagulant drugs
Number of subjects: 1185
Study: 24499060

Group type: EXPERIMENTAL
Intervention: CLIMATE Schools Combined intervention
Number of subjects: 8400

Group type: COMPARATOR
Intervention: CLIMATE Schools - Substance Use
Number of subjects: 8400

Group type: COMPARATOR
Intervention: CLIMATE Schools - Mental Health
Number of subjects: 8400

Group type: COMPARATOR
Intervention: Control (Health and Physical Education as usual)
Number of subjects: 8400
Study: 22527794

Group type: EXPERIMENTAL
Intervention: Revascularization (REV)
Number of subjects: 1505

Group type: COMPARATOR
Intervention: Intensive medical therapy (MED)
Number of subjects: 1505

Group type: EXPERIMENTAL
Intervention: Coronary artery bypass grafting (CABG)
Number of subjects: 1505

Group type: EXPERIMENTAL
Intervention: Percutaneous coronary intervention (PCI)
Number of subjects: 1505

Group type: EXPERIMENTAL
Intervention: Stress myocardial perfusion abnormalities
Number of subjects: 1505
Study: 20128041

Group type: EXPERIMENTAL
Intervention: Feiji Recipe
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Feiji Recipe combined with chemotherapy
Number of subjects: 60

Group type: COMPARATOR
Intervention: Chemotherapy (vinorelbine plus cisplatin or gemcitabine plus cisplatin)
Number of subjects: 60
Study: 18154417

Group type: EXPERIMENTAL
Intervention: Suprapapillary needle‐knife fistulotomy (group B)
Number of subjects: 218

Group type: COMPARATOR
Intervention: Standard cannulation (group A)
Number of subjects: 218
Study: 16417182

Group type: EXPERIMENTAL
Intervention: Montelukast added to previous medication for asthma treatment (4 weeks duration)
Number of subjects: 703

Group type: EXPERIMENTAL
Intervention: Montelukast added to previous medication for asthma treatment (8 weeks duration)
Number of subjects: 703
Study: 12218520

Group type: EXPERIMENTAL
Intervention: Gabapentin (1,200 mg)
Number of subjects: 70

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 70
Study: 10604663

Group type: EXPERIMENTAL
Intervention: Early photocoagulation
Number of subjects: 205

Group type: COMPARATOR
Intervention: Deferral of photocoagulation
Number of subjects: 205

Group type: EXPERIMENTAL
Intervention: All eyes with mild to moderate nonproliferative diabetic retinopathy before lens surgery
Number of subjects: 205

Group type: EXPERIMENTAL
Intervention: Eyes with severe nonproliferative or worse retinopathy before lens surgery
Number of subjects: 205

Group type: EXPERIMENTAL
Intervention: Lens surgery
Number of subjects: 205
Study: 7550184

Group type: EXPERIMENTAL
Intervention: Oral bromfenac
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Sublingual buprenorphine
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: McGill Pain Questionnaire (MPQ)
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: 10 cm Visual Analogue Scale
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Four word scale
Number of subjects: 75